Literature DB >> 10400341

Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.

T C McMorris1.   

Abstract

Hydroxymethylacylfulvene (HMAF, MGI 114) is derived from the sesquiterpene illudin S by treatment with dilute sulfuric acid and excess paraformaldehyde. It is less cytotoxic than illudin S but exhibits much greater selectivity in toxicity to malignant cells compared to normal cells. HMAF is believed to undergo bioreductive activation in vivo. It is now being tested in human clinical phase II trials against solid tumors.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10400341     DOI： 10.1016/s0968-0896(99)00016-4

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  10 in total

1.  Chemical and enzymatic reductive activation of acylfulvene to isomeric cytotoxic reactive intermediates.

Authors:  Kathryn E Pietsch; James F Neels; Xiang Yu; Jiachang Gong; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2011-10-14       Impact factor: 3.739

2.  Draft genome of Omphalotus olearius provides a predictive framework for sesquiterpenoid natural product biosynthesis in Basidiomycota.

Authors:  Grayson T Wawrzyn; Maureen B Quin; Swati Choudhary; Fernando López-Gallego; Claudia Schmidt-Dannert
Journal:  Chem Biol       Date:  2012-06-22

3.  Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Authors:  F Giles; J Cortes; G Garcia-Manero; S Kornblau; E Estey; M Kwari; A Murgo; H Kantarjian
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

4.  Studies on the mechanism of action of prekinamycin, a member of the diazoparaquinone family of natural products: evidence for both sp2 radical and orthoquinonemethide intermediates.

Authors:  Ken S Feldman; Kyle J Eastman
Journal:  J Am Chem Soc       Date:  2006-09-27       Impact factor: 15.419

5.  A proposal for the mechanism-of-action of diazoparaquinone natural products.

Authors:  Ken S Feldman; Kyle J Eastman
Journal:  J Am Chem Soc       Date:  2005-11-09       Impact factor: 15.419

6.  Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks.

Authors:  Lillibeth Chaverra-Muñoz; Theresa Briem; Stephan Hüttel
Journal:  Microb Cell Fact       Date:  2022-05-28       Impact factor: 6.352

7.  Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.

Authors:  Russell J Schilder; John A Blessing; Michael L Pearl; Peter G Rose
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

Review 8.  Mushrooms: an emerging resource for therapeutic terpenoids.

Authors:  Adhiraj Dasgupta; Krishnendu Acharya
Journal:  3 Biotech       Date:  2019-09-24       Impact factor: 2.406

9.  A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications.

Authors:  Umesh Kathad; Aditya Kulkarni; Joseph Ryan McDermott; Jordan Wegner; Peter Carr; Neha Biyani; Rama Modali; Jean-Philippe Richard; Panna Sharma; Kishor Bhatia
Journal:  BMC Bioinformatics       Date:  2021-03-02       Impact factor: 3.169

10.  RFWD3 and translesion DNA polymerases contribute to PCNA modification-dependent DNA damage tolerance.

Authors:  Rie Kanao; Hidehiko Kawai; Toshiyasu Taniguchi; Minoru Takata; Chikahide Masutani
Journal:  Life Sci Alliance       Date:  2022-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.